Geoff Kuziemko

Partner

Disclaimer

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Dr. Geoff Kuziemko focuses his practice on assisting clients, primarily in the life sciences sector, with intellectual property and technology-intense transactions. His work runs the gamut of complex transactions, from out-bound license and in-bound license, development, commercialization, strategic alliance and joint venture, collaboration, and profit sharing agreements to commercial agreements for distribution, manufacture, and supply, as well as intellectual property due diligence for strategic acquisitions and financings involving life sciences businesses, products, and patents.

Geoff was previously the Vice President of Legal Services at a multi-billion, NASDAQ-listed genomics company, Exelixis, Inc., based in Northern California.  

Admissions

Bar Admissions

  • California

Court Admissions

  • California Supreme Court

Education

  • Hastings College of the Law, J.D., 2000; cum laude; Order of the Coif 
  • University of California, Berkeley, Ph.D., Biophysical Chemistry, 1997
  • Massachusetts Institute of Technology, B.S., Chemistry, 1992;  MIT Undergraduate Research Opportunities Program Award

Professional Activities

Member

  • California Bar Association

Speaker

  • 2019 China Renaissance Healthcare Event (January 10th, 2019)
  • “Addressing Risk and Opportunities in Life Sciences IP Due Diligence,” The Knowledge Group (November 14th, 2018)
  • Drafting and negotiating a collaboration for a variety of cell therapy programs 
  • Drafting and negotiating an exclusive outlicense of transmembrane immunomodulatory protein technology, valued at more than US$535 million 
  • Drafting and negotiating a worldwide profit share collaboration for six biosimilar programs, including upfront and milestone payments of US$245 million 
  • Drafting and negotiating a genomics alliance agreement for the discovery and development of novel therapeutic approaches to major chronic diseases within oncology, neuroscience, and immunology
  • Drafting and negotiating separate US and EU commercial manufacturing and supply agreements for a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma
VIEW MORE

Press Releases